JP2024526155A5 - - Google Patents
Info
- Publication number
- JP2024526155A5 JP2024526155A5 JP2023578891A JP2023578891A JP2024526155A5 JP 2024526155 A5 JP2024526155 A5 JP 2024526155A5 JP 2023578891 A JP2023578891 A JP 2023578891A JP 2023578891 A JP2023578891 A JP 2023578891A JP 2024526155 A5 JP2024526155 A5 JP 2024526155A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214769P | 2021-06-24 | 2021-06-24 | |
| US63/214,769 | 2021-06-24 | ||
| US202163277550P | 2021-11-09 | 2021-11-09 | |
| US63/277,550 | 2021-11-09 | ||
| US202163280521P | 2021-11-17 | 2021-11-17 | |
| US63/280,521 | 2021-11-17 | ||
| US202263321615P | 2022-03-18 | 2022-03-18 | |
| US63/321,615 | 2022-03-18 | ||
| PCT/US2022/034754 WO2022271964A1 (en) | 2021-06-24 | 2022-06-23 | Erk1/2 and shp2 inhibitors combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024526155A JP2024526155A (ja) | 2024-07-17 |
| JP2024526155A5 true JP2024526155A5 (https=) | 2025-06-24 |
| JPWO2022271964A5 JPWO2022271964A5 (https=) | 2025-06-24 |
Family
ID=84545944
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023578891A Withdrawn JP2024526155A (ja) | 2021-06-24 | 2022-06-23 | Ｅｒｋ１／２およびｓｈｐ２阻害剤の併用療法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240299388A1 (https=) |
| EP (1) | EP4358965A4 (https=) |
| JP (1) | JP2024526155A (https=) |
| KR (1) | KR20240096444A (https=) |
| AU (1) | AU2022300368A1 (https=) |
| CA (1) | CA3222772A1 (https=) |
| IL (1) | IL309401A (https=) |
| MX (1) | MX2023015298A (https=) |
| TW (1) | TW202317124A (https=) |
| WO (1) | WO2022271964A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016205418A1 (en) * | 2015-06-15 | 2016-12-22 | Asana Biosciences, Llc | Heterocyclic inhibitors of erk1 and erk2 and their use in the treatment of cancer |
| CA3074690A1 (en) * | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| JP7542538B2 (ja) * | 2018-09-18 | 2024-08-30 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体 |
| CA3158910A1 (en) * | 2019-10-28 | 2021-05-06 | Asana Biosciences, Llc | Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2 |
-
2022
- 2022-06-23 MX MX2023015298A patent/MX2023015298A/es unknown
- 2022-06-23 EP EP22829313.0A patent/EP4358965A4/en not_active Withdrawn
- 2022-06-23 US US18/572,404 patent/US20240299388A1/en active Pending
- 2022-06-23 KR KR1020247002544A patent/KR20240096444A/ko active Pending
- 2022-06-23 AU AU2022300368A patent/AU2022300368A1/en active Pending
- 2022-06-23 IL IL309401A patent/IL309401A/en unknown
- 2022-06-23 JP JP2023578891A patent/JP2024526155A/ja not_active Withdrawn
- 2022-06-23 CA CA3222772A patent/CA3222772A1/en active Pending
- 2022-06-23 WO PCT/US2022/034754 patent/WO2022271964A1/en not_active Ceased
- 2022-06-23 TW TW111123544A patent/TW202317124A/zh unknown